Literature DB >> 26912050

[Immunomodulation as innovative therapy for head and neck tumors : Current developments].

P J Schuler1, J C Doescher2, S Laban2, T K Hoffmann2.   

Abstract

Head and neck squamous cell carcinoma (HNSCC) is characterized by its intense immune suppression and its elaborate immune escape mechanisms. Due to the fact that survival rates remain low, the role of immunotherapy has become more important and the focus of current clinical studies has shifted toward antibody-based immune checkpoint modulation. Application of immunotherapy in curative settings or for prevention of recurrent disease would be desirable.

Entities:  

Keywords:  Head and neck neoplasms; Immunotherapy; Monoclonal antibodies; Programmed cell death 1 receptor; Vaccination

Mesh：

Substances：

Year:  2016        PMID： 26912050     DOI： 10.1007/s00106-016-0131-0

Source DB:  PubMed          Journal:  HNO        ISSN： 0017-6192            Impact factor:   1.284


  31 in total

1.  A phase 1 safety study of an IRX-2 regimen in patients with squamous cell carcinoma of the head and neck.

Authors:  Scott M Freeman; Jose Luis Barrera Franco; Daniel E Kenady; Lorraine Baltzer; Zygmund Roth; Harvey J Brandwein; John W Hadden
Journal:  Am J Clin Oncol       Date:  2011-04       Impact factor: 2.339

2.  Effective treatment of metastatic forms of Epstein-Barr virus-associated nasopharyngeal carcinoma with a novel adenovirus-based adoptive immunotherapy.

Authors:  Corey Smith; Janice Tsang; Leone Beagley; Daniel Chua; Victor Lee; Vivian Li; Denis J Moss; William Coman; Kwok H Chan; John Nicholls; Dora Kwong; Rajiv Khanna
Journal:  Cancer Res       Date:  2012-01-26       Impact factor: 12.701

3.  Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy.

Authors:  Steven A Rosenberg; James C Yang; Richard M Sherry; Udai S Kammula; Marybeth S Hughes; Giao Q Phan; Deborah E Citrin; Nicholas P Restifo; Paul F Robbins; John R Wunderlich; Kathleen E Morton; Carolyn M Laurencot; Seth M Steinberg; Donald E White; Mark E Dudley
Journal:  Clin Cancer Res       Date:  2011-04-15       Impact factor: 12.531

4.  Phase II clinical trial of multiple peptide vaccination for advanced head and neck cancer patients revealed induction of immune responses and improved OS.

Authors:  Yoshihiro Yoshitake; Daiki Fukuma; Akira Yuno; Masatoshi Hirayama; Hideki Nakayama; Takuya Tanaka; Masashi Nagata; Yasuo Takamune; Kenta Kawahara; Yoshihiro Nakagawa; Ryoji Yoshida; Akiyuki Hirosue; Hidenao Ogi; Akimitsu Hiraki; Hirofumi Jono; Akinobu Hamada; Koji Yoshida; Yasuharu Nishimura; Yusuke Nakamura; Masanori Shinohara
Journal:  Clin Cancer Res       Date:  2014-11-12       Impact factor: 12.531

5.  Phase I dendritic cell p53 peptide vaccine for head and neck cancer.

Authors:  Patrick J Schuler; Malgorzata Harasymczuk; Carmen Visus; Albert Deleo; Sumita Trivedi; Yu Lei; Athanassios Argiris; William Gooding; Lisa H Butterfield; Theresa L Whiteside; Robert L Ferris
Journal:  Clin Cancer Res       Date:  2014-02-28       Impact factor: 12.531

6.  Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase.

Authors:  Catherine Uyttenhove; Luc Pilotte; Ivan Théate; Vincent Stroobant; Didier Colau; Nicolas Parmentier; Thierry Boon; Benoît J Van den Eynde
Journal:  Nat Med       Date:  2003-09-21       Impact factor: 53.440

7.  Nivolumab plus ipilimumab in advanced melanoma.

Authors:  Jedd D Wolchok; Harriet Kluger; Margaret K Callahan; Michael A Postow; Naiyer A Rizvi; Alexander M Lesokhin; Neil H Segal; Charlotte E Ariyan; Ruth-Ann Gordon; Kathleen Reed; Matthew M Burke; Anne Caldwell; Stephanie A Kronenberg; Blessing U Agunwamba; Xiaoling Zhang; Israel Lowy; Hector David Inzunza; William Feely; Christine E Horak; Quan Hong; Alan J Korman; Jon M Wigginton; Ashok Gupta; Mario Sznol
Journal:  N Engl J Med       Date:  2013-06-02       Impact factor: 91.245

8.  Phenotypic and functional characteristics of CD4+ CD39+ FOXP3+ and CD4+ CD39+ FOXP3neg T-cell subsets in cancer patients.

Authors:  Patrick J Schuler; Bastian Schilling; Malgorzata Harasymczuk; Thomas K Hoffmann; Jonas Johnson; Stephan Lang; Theresa L Whiteside
Journal:  Eur J Immunol       Date:  2012-06-18       Impact factor: 5.532

9.  Alterations in the frequency of dendritic cell subsets in the peripheral circulation of patients with squamous cell carcinomas of the head and neck.

Authors:  Thomas K Hoffmann; Jan Müller-Berghaus; Robert L Ferris; Jonas T Johnson; Walter J Storkus; Theresa L Whiteside
Journal:  Clin Cancer Res       Date:  2002-06       Impact factor: 12.531

10.  Phase II evaluation of dalantercept, a soluble recombinant activin receptor-like kinase 1 (ALK1) receptor fusion protein, for the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study 0229N.

Authors:  Vicky Makker; Virginia L Filiaci; Lee-May Chen; Christopher J Darus; James E Kendrick; Gregory Sutton; Katherine Moxley; Carol Aghajanian
Journal:  Gynecol Oncol       Date:  2015-04-16       Impact factor: 5.482
View more
  1 in total

Review 1.  [Immunotherapy for HNSCC : Quo vadis?].

Authors:  J Döscher; C-J Busch; P J Schuler; S Laban
Journal:  HNO       Date:  2016-10       Impact factor: 1.284
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.